HEILONGJIANG ZBD PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12 CNY | +5.36% |
|
+9.59% | -1.32% |
| Sales 2022 | 4.21B 582M 797M | Sales 2023 | 3.14B 434M 594M | Capitalization | 11.42B 1.58B 2.16B |
|---|---|---|---|---|---|
| Net income 2022 | 185M 25.54M 34.98M | Net income 2023 | 473M 65.3M 89.43M | EV / Sales 2022 | 3.29 x |
| Net Debt 2022 | 1.86B 257M 353M | Net Debt 2023 | 1.7B 234M 321M | EV / Sales 2023 | 4.17 x |
| P/E ratio 2022 |
64.8
x | P/E ratio 2023 |
24.2
x | Employees | 2,760 |
| Yield 2022 |
0.22% | Yield 2023 |
-
| Free-Float | 23.66% |
More Fundamentals
* Assessed data
More news
| 1 day | +5.36% | ||
| 1 week | +9.59% | ||
| Current month | +14.29% | ||
| 1 month | +14.29% | ||
| 3 months | +9.49% | ||
| 6 months | -6.32% | ||
| Current year | -1.32% |
1 week
10.83
12.06
1 month
10.4512.06
Current year
8.8912.50
1 year
8.8917.87
3 years
8.8919.22
5 years
8.8919.22
10 years
8.8960.16
| Managers | Title | Age | Since |
|---|---|---|---|
Jiu Liang Yan
CEO | Chief Executive Officer | 46 | 16-12-31 |
Tong Hua Fang
FOU | Founder | 61 | 96-10-27 |
Lei Wang
DFI | Director of Finance/CFO | 43 | 19-09-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yun Qi Zhang
BRD | Director/Board Member | 60 | 19-05-16 |
Tong Hua Fang
FOU | Founder | 61 | 96-10-27 |
Pei Bao Lan
CHM | Chairman | 51 | 02-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.43% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 12 | +5.36% | 10,378,890 |
| 24-04-26 | 11.39 | +2.34% | 7,240,800 |
| 24-04-25 | 11.13 | +1.92% | 6,655,239 |
| 24-04-24 | 10.92 | -2.85% | 7,485,568 |
| 24-04-23 | 11.24 | +2.65% | 5,972,801 |
End-of-day quote Shanghai S.E., April 28, 2024
More quotes
HeiLongJiang ZBD Pharmaceutical Co., Ltd. is a China-based pharmaceutical company engaged in the research and development, manufacture and sales of Chinese patent medicine. The Company's products include freeze-dried powder injections, powder injections, large volume injections, small volume injections, mixture, tablets, capsule, granules, syrup, oral solution, decoction agent and active pharmaceutical ingredient, which are used for the areas of cardiovascular, anti-viral flu, fracture and osteoporosis, immune enhancement and liver protection. The Company distributes its products under the brand named Zhenbaodao.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q1 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -1.32% | 1.56B | |
| +26.47% | 664B | |
| +26.74% | 567B | |
| -6.33% | 354B | |
| +19.35% | 330B | |
| +4.23% | 286B | |
| +13.43% | 234B | |
| +4.71% | 199B | |
| -9.53% | 196B | |
| -4.04% | 148B |
- Stock Market
- Equities
- 603567 Stock
